ABUS
Arbutus Biopharma Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-27/100
Last price
4.48
▼ 0.19 (4.07%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.67
Day high
4.67
Day low
4.43
Volume
8.26M
Market cap
$686.68M
P/E (TTM)
5.67
52W range
3.50 – 5.45
Trailing performance
Returnvs SPY
1W
-4.48%
-6.4%
1M
-13.01%
-14.2%
3M
-14.18%
-18.7%
6M
+0.45%
-17.7%
YTD
-6.86%
-21.1%
1Y
+2.28%
-14.1%
3Y
+120.69%
+38.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on ABUS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
31.44M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 18, 26 | BEARDSLEY ROBERT A Director |
CONVERSION | 131.33K | $502.22K | Direct |
| Sep 18, 26 | SAWHNEY ROGER M.D. Director |
CONVERSION | 131.33K | $509.57K | Direct |
| Sep 18, 26 | ANDROSKI LINDSAY J.D. Chief Executive Officer |
CONVERSION | 126.86K | $418.41K | Direct |
| Sep 18, 26 | NGUYEN TUAN Chief Financial Officer |
CONVERSION | 293.10K | $1.05M | Direct |
| Feb 2, 26 | ANDROSKI LINDSAY J.D. Chief Executive Officer |
STOCK | 28.00K | $0 | Direct |
| Feb 2, 26 | NGUYEN TUAN Chief Financial Officer |
STOCK | 73.50K | $0 | Direct |
| Feb 14, 25 | NAFTZGER J CHRISTOPHER General Counsel |
STOCK | 54.30K | $0 | Direct |
| Feb 14, 25 | HASTINGS DAVID C Chief Financial Officer |
STOCK | 90.10K | $0 | Direct |
| Feb 14, 25 | SIMS KAREN Officer |
STOCK | 49.30K | $0 | Direct |
| Feb 4, 25 | NAFTZGER J CHRISTOPHER General Counsel |
SELL | 11.33K | $37.21K | Direct |
| Feb 4, 25 | HASTINGS DAVID C Chief Financial Officer |
SELL | 22.18K | $72.83K | Direct |
| Feb 4, 25 | SIMS KAREN Officer |
SELL | 19.35K | $63.52K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDROSKI LINDSAY J.D. |
Chief Executive Officer | 72.34K | Conversion of Exercise of derivative security |
BEARDSLEY ROBERT A |
Director | 32.28K | Conversion of Exercise of derivative security |
HASTINGS DAVID C |
Chief Financial Officer | 249.82K | Stock Award(Grant) |
NAFTZGER J CHRISTOPHER |
General Counsel | 140.54K | Stock Award(Grant) |
NGUYEN TUAN |
Chief Financial Officer | 159.96K | Conversion of Exercise of derivative security |
SAWHNEY ROGER M.D. |
Director | 30.82K | Conversion of Exercise of derivative security |
SIMS KAREN |
Officer | 155.49K | Stock Award(Grant) |
Fundamentals
Market cap$686.68M
Enterprise value$797.36M
Revenue (TTM)$181.72M
Gross profit$163.92M
EBITDA$147.47M
Net income$153.05M
EPS (TTM)$0.79
Free cash flow$-80.24M
Total cash$92.63M
Total debt$3.63M
Book value / share$1.31
Shares outstanding153.28M
Float122.36M
Short % of float13.86%
Dividend yield0.00%
Beta (5Y)0.76
Valuation & profitability ratios
Trailing P/E5.67
Forward P/E-27.10
PEG ratio—
Price / sales—
Price / book3.42
EV / revenue4.39
EV / EBITDA5.41
Gross margin90.20%
Operating margin-567.16%
Profit margin84.23%
Return on equity89.58%
Return on assets48.84%
Debt / equity1.40
Current ratio81.42
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $14.08M | $6.17M | $18.14M | $39.02M | — | +128.2% |
| Operating revenue | $14.08M | $6.17M | $18.14M | $39.02M | — | +128.2% |
| Research & development | $25.24M | $54.04M | $73.70M | $84.41M | — | -53.3% |
| Selling, general & admin | $15.89M | $22.11M | $22.48M | $17.83M | — | -28.1% |
| Total operating expense | $41.13M | $76.14M | $96.17M | $102.24M | — | -46.0% |
| Operating income | -$27.05M | -$69.97M | -$78.03M | -$63.22M | — | +61.3% |
| Net interest income | $3.97M | $6.45M | $5.23M | $466.00K | — | -38.4% |
| Pre-tax income | -$33.50M | -$69.92M | -$72.85M | -$65.01M | — | +52.1% |
| Tax provision | — | $0 | $0 | $4.44M | $0 | — |
| Net income | -$33.50M | -$69.92M | -$72.85M | -$69.46M | — | +52.1% |
| Net income to common | -$33.50M | -$69.92M | -$72.85M | -$69.46M | — | +52.1% |
| Basic EPS | -0.17 | -0.38 | -0.44 | -0.46 | — | +55.3% |
| Diluted EPS | -0.17 | -0.38 | -0.44 | -0.46 | — | +55.3% |
| EBIT | -$33.40M | -$69.78M | -$72.39M | -$63.29M | — | +52.1% |
| EBITDA | -$33.04M | -$68.40M | -$70.99M | -$61.86M | — | +51.7% |
| Basic shares | 191.60M | 185.61M | 165.96M | 150.94M | — | +3.2% |
| Diluted shares | 191.60M | 185.61M | 165.96M | 150.94M | — | +3.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $18.01M | $36.33M | $26.29M | $30.78M | -50.4% |
| Cash & short-term investments | $91.47M | $122.62M | $126.00M | $146.91M | -25.4% |
| Accounts receivable | $1.45M | $2.41M | $1.78M | $1.35M | -39.9% |
| Total current assets | $94.46M | $127.32M | $132.03M | $151.14M | -25.8% |
| Property, plant & equipment | $32.00K | $4.36M | $6.09M | $6.81M | -99.3% |
| Total assets | $94.62M | $131.71M | $144.40M | $195.42M | -28.2% |
| Total current liabilities | $6.01M | $15.62M | $22.49M | $32.86M | -61.5% |
| Total debt | $746.00K | $1.29M | $1.77M | $2.19M | -42.1% |
| Total liabilities | $18.04M | $34.34M | $38.38M | $58.57M | -47.5% |
| Retained earnings | -$1.38B | -$1.35B | -$1.28B | -$1.20B | -2.5% |
| Shareholder equity | $76.58M | $97.37M | $106.02M | $136.85M | -21.4% |
| Working capital | $88.45M | $111.70M | $109.54M | $118.28M | -20.8% |
| Net tangible assets | $76.58M | $97.37M | $106.02M | $136.85M | -21.4% |
| Shares issued | 192.53M | 189.96M | 169.87M | 157.46M | +1.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$33.50M | -$69.92M | -$72.85M | -$69.46M | — | +52.1% |
| Depreciation & amortisation | $363.00K | $1.38M | $1.40M | $1.43M | — | -73.7% |
| Stock-based compensation | $6.95M | $8.99M | $9.30M | $7.18M | — | -22.6% |
| Change in working capital | -$10.02M | -$2.83M | -$18.23M | $29.24M | — | -254.3% |
| Operating cash flow | -$39.64M | -$64.85M | -$85.94M | -$35.36M | — | +38.9% |
| Capital expenditure | — | -$182.00K | -$1.01M | -$512.00K | -$809.00K | — |
| Investing cash flow | $15.58M | $22.95M | $50.77M | -$74.94M | — | -32.1% |
| Financing cash flow | $5.72M | $52.00M | $30.65M | $31.81M | — | -89.0% |
| Free cash flow | -$39.64M | -$65.03M | -$86.94M | -$35.87M | — | +39.1% |
| End cash position | $18.01M | $36.33M | $26.29M | $30.78M | — | -50.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.01M | $179.13M | $1.05M | $529.00K | $10.74M | — | -99.4% |
| Operating revenue | $1.01M | $179.13M | $1.05M | $529.00K | $10.74M | — | -99.4% |
| Research & development | $2.90M | $4.12M | $5.01M | $5.78M | $5.50M | — | -29.7% |
| Selling, general & admin | $3.87M | $5.89M | $3.69M | $3.04M | $3.33M | — | -34.3% |
| Total operating expense | $6.76M | $10.01M | $8.70M | $8.82M | $8.83M | — | -32.4% |
| Operating income | -$5.75M | $169.12M | -$7.64M | -$8.29M | $1.91M | — | -103.4% |
| Net interest income | $824.00K | $798.00K | $859.00K | $929.00K | $1.01M | — | +3.3% |
| Pre-tax income | -$5.14M | $169.69M | -$3.76M | -$7.74M | $2.52M | — | -103.0% |
| Net income | -$5.14M | $169.69M | -$3.76M | -$7.74M | $2.52M | — | -103.0% |
| Net income to common | -$5.14M | $169.69M | -$3.76M | -$7.74M | $2.52M | — | -103.0% |
| Basic EPS | -0.03 | 0.88 | — | -0.04 | 0.01 | -0.13 | -103.4% |
| Diluted EPS | -0.03 | 0.87 | — | -0.04 | 0.01 | -0.13 | -103.4% |
| EBIT | -$5.13M | $169.71M | -$3.74M | -$7.72M | $2.55M | — | -103.0% |
| EBITDA | -$5.11M | $169.72M | -$3.73M | -$7.71M | $2.56M | — | -103.0% |
| Basic shares | 197.47M | 193.77M | — | 191.78M | 191.55M | 190.71M | +1.9% |
| Diluted shares | 197.47M | 195.21M | — | 191.78M | 192.40M | 190.71M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.17M | $23.71M | $18.01M | $22.41M | $37.41M | -19.1% |
| Cash & short-term investments | $92.63M | $95.23M | $91.47M | $93.70M | $98.09M | -2.7% |
| Accounts receivable | $369.00K | $1.31M | $1.45M | $905.00K | $1.02M | -71.9% |
| Total current assets | $273.88M | $277.01M | $94.46M | $97.44M | $103.12M | -1.1% |
| Property, plant & equipment | $10.00K | $22.00K | $32.00K | $137.00K | $148.00K | -54.5% |
| Total assets | $274.02M | $277.16M | $94.62M | $97.71M | $103.27M | -1.1% |
| Total current liabilities | $3.36M | $5.11M | $6.01M | $5.18M | $5.02M | -34.1% |
| Total debt | $514.00K | $631.00K | $746.00K | $922.00K | $1.09M | -18.5% |
| Total liabilities | $15.29M | $16.99M | $18.04M | $20.31M | $20.29M | -10.0% |
| Retained earnings | -$1.22B | -$1.21B | -$1.38B | -$1.38B | -$1.37B | -0.4% |
| Shareholder equity | $258.73M | $260.18M | $76.58M | $77.40M | $82.98M | -0.6% |
| Working capital | $270.52M | $271.91M | $88.45M | $92.26M | $98.10M | -0.5% |
| Net tangible assets | $258.73M | $260.18M | $76.58M | $77.40M | $82.98M | -0.6% |
| Shares issued | 197.63M | 196.95M | 192.53M | 191.95M | 191.64M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$5.14M | $169.69M | -$3.76M | -$7.74M | $2.52M | -103.0% |
| Depreciation & amortisation | $11.00K | $11.00K | $11.00K | $11.00K | $11.00K | 0.0% |
| Stock-based compensation | $1.63M | $1.36M | $1.26M | $1.26M | $864.00K | +19.6% |
| Change in working capital | -$2.24M | -$178.87M | $1.80M | $1.15M | -$18.24M | +98.7% |
| Operating cash flow | -$6.02M | -$8.11M | -$4.68M | -$5.82M | -$15.75M | +25.8% |
| Investing cash flow | -$1.66M | $2.20M | -$1.36M | -$10.02M | $15.61M | -175.5% |
| Financing cash flow | $3.15M | $11.62M | $1.64M | $844.00K | $453.00K | -72.9% |
| Free cash flow | -$6.02M | -$8.11M | -$4.68M | -$5.82M | -$15.75M | +25.8% |
| End cash position | $19.17M | $23.71M | $18.01M | $22.41M | $37.41M | -19.1% |
Options analytics
Put / call volume
1.02
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
3.00
-33.0% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
12.61K
Contracts, this expiry
Put volume
12.91K
Contracts, this expiry
Heaviest call OI
3.00
0 contracts
Heaviest put OI
4.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.03 | -0.04 | -54.8% |
| Mar 2026 | -0.06 | 1.19 | +2,270.6% |
| Dec 2025 | -0.06 | -0.01 | +75.1% |
| Sep 2025 | -0.05 | -0.06 | -21.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.03 | 1 | $1.39M | +87.4% |
| Next quarter | -0.03 | 1 | $1.39M | -3.7% |
| Current year | 1.03 | 1 | $252.84M | +1,208.8% |
| Next year | -0.11 | 1 | $5.69M | -97.8% |
Analyst targets & ownership
Mean target$5.36
High target$5.36
Low target$5.36
Implied upside19.74%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders15.89%
Held by institutions66.92%
Institutions holding231
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.71
-4.82% from price
SMA 20
4.89
-8.39% from price
SMA 50
4.84
-7.43% from price
SMA 100
4.68
-4.18% from price
SMA 200
4.54
-1.28% from price
EMA 12
4.72
-5.14% from price
EMA 26
4.83
-7.23% from price
EMA 50
4.82
-7.05% from price
RSI (14)
35.2
Neutral
MACD (12,26,9)
-0.11
Hist -0.06
ATR (14)
0.17
3.84% of price
Realised vol 30D
28.8%
Annualised
Bollinger upper
5.33
20, 2σ
Bollinger lower
4.46
20, 2σ
50 / 200 cross
Golden
4.84 vs 4.54
Trend bias
Below 200
-1.28%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.15
More volatile than market
Correlation to SPY
0.33
Loosely linked
Realised vol 30D
28.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-25.9%
Peak to trough
Max drawdown 5Y
-63.3%
Peak to trough
ATR 14
0.17
3.84% of price
Beta (reported)
0.76
5Y monthly, from filing
Short interest
Shares short
18.48M
Prior 18.46M
Change vs prior
+0.2%
Shorts adding
% of float
13.86%
Elevated
% of shares out
9.33%
Against total outstanding
Days to cover
3.7
Liquid
Float
122.36M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Aug 11, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Mar 28, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jan 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 20, 24 | Chardan Capital | MAINTAINED | Buy | Buy |
| Nov 18, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 7, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 7, 24 | Chardan Capital | MAINTAINED | Buy | Buy |
| Sep 5, 24 | Jefferies | MAINTAINED | Buy | Buy |
| Aug 2, 24 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Jun 7, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 6, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:5
Split dateNov 4, 2010
SEC filings
Tender Offer/Acquisition Reports
SC TO-I/A · 2026-10-01
Tender Offer/Acquisition Reports
SC TO-I/A · 2026-09-30
Tender Offer/Acquisition Reports
SC TO-I · 2026-08-24
Corporate Changes & Voting Matters
8-K · 2026-08-21
Periodic Financial Reports
10-Q · 2026-08-12
Corporate Changes & Voting Matters
8-K · 2026-07-16
Offering Registrations
S-8 · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-05-27
Headlines
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
GlobeNewswire · 6d ago
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
GlobeNewswire · 7d ago
Health Care Roundup: Market Talk
The Wall Street Journal · 42d ago
Arbutus Biopharma Launches $230 Million Tender Offer for Common Shares
MT Newswires · 44d ago
Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
GlobeNewswire · 44d ago
Sector Update: Healthcare Stocks Advance Late Afternoon
MT Newswires · 47d ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 47d ago
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
InvestorsHub · 47d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.